Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Boosts Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Loring Wolcott & Coolidge Fiduciary Advisors LLP increased its stake in Regeneron Pharmaceuticals by 3.6%, holding 99,913 shares valued at $52.45 million.
• Regeneron reported $12.89 earnings per share for the last quarter, significantly surpassing analysts' estimates of $8.43, while also experiencing a 3.6% increase in revenue year over year.
• The company announced a quarterly dividend of $0.88 per share, yielding approximately 0.6%, with a payout ratio of 8.87%.

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 3.6% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 99,913 shares of the biopharmaceutical company's stock after buying an additional 3,440 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA owned 0.09% of Regeneron Pharmaceuticals worth $52,454,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of REGN. Activest Wealth Management raised its position in Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 21 shares during the last quarter. Costello Asset Management INC purchased a new position in Regeneron Pharmaceuticals during the 1st quarter worth approximately $27,000. Saudi Central Bank purchased a new position in Regeneron Pharmaceuticals during the 1st quarter worth approximately $27,000. Colonial Trust Advisors purchased a new position in Regeneron Pharmaceuticals during the 1st quarter worth approximately $32,000. Finally, SouthState Corp raised its position in Regeneron Pharmaceuticals by 550.0% during the 1st quarter. SouthState Corp now owns 52 shares of the biopharmaceutical company's stock worth $33,000 after buying an additional 44 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $584.74 on Thursday. The company's fifty day moving average price is $576.17 and its 200 day moving average price is $562.42. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $959.60. The stock has a market capitalization of $61.98 billion, a P/E ratio of 14.74, a P/E/G ratio of 1.81 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm had revenue of $3.68 billion for the quarter, compared to analysts' expectations of $3.30 billion. During the same quarter last year, the company earned $11.56 EPS. The firm's revenue for the quarter was up 3.6% compared to the same quarter last year. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals's payout ratio is 8.87%.

Analyst Ratings Changes

Several research firms have recently weighed in on REGN. Wells Fargo & Company lowered shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 target price for the company. in a report on Friday, August 1st. Rothschild & Co Redburn began coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, August 14th. They set a "buy" rating and a $890.00 target price for the company. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 8th. Redburn Atlantic raised shares of Regeneron Pharmaceuticals to a "strong-buy" rating in a report on Thursday, August 14th. Finally, Guggenheim lifted their target price on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a "buy" rating in a report on Friday, August 1st. Three analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $817.88.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.